<i>ASXL1</i> truncating mutations drive leukemic resistance to T cell attack
Dustin McCurry(The University of Texas MD Anderson Cancer Center), Pavan Bachireddy(The University of Texas MD Anderson Cancer Center), Zhongqi Ge(The University of Texas MD Anderson Cancer Center), Bijal Thakkar(The University of Texas MD Anderson Cancer Center), Vinhkhang N. Nguyen(Harvard University), Catherine J. Wu(Dana-Farber Cancer Institute), Jeffrey J. Molldrem(The University of Texas MD Anderson Cancer Center), Katie Maurer(Broad Institute), Kenneth J. Livak(Broad Institute), Robert J. Soiffer(Dana-Farber Cancer Institute), Thomas Köhnke(California Institute for Regenerative Medicine), Oren Pasvolsky(The University of Texas MD Anderson Cancer Center), Ravindra Majeti(Stanford University), Elham Azizi(Columbia University Irving Medical Center), Sachet A. Shukla(The University of Texas MD Anderson Cancer Center), Pranaya Raparla(The University of Texas MD Anderson Cancer Center), Shuqiang Li(Beijing Institute of Technology), Xiaohong Leng(Zhejiang University), Rishi Pasumarthi(The University of Texas MD Anderson Cancer Center), Jerome Ritz(Dana-Farber Cancer Institute), Emerie E Danson(The University of Texas MD Anderson Cancer Center), Jae‐Hyun Lee(Yonsei University)
Cited by 0